COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment
COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment
复制标题
DOI：
10.1177/1352458520943783
复制
发表时间：
2020-08-07
影响因子：
5.8
通讯作者：
Berger, Benjamin
中科院分区：
文献类型：
--
作者：
Dersch, Rick;Wehrum, Thomas;Berger, Benjamin
背景：大多数 COVID-19 病例被认为是轻度病例，但接受免疫抑制剂治疗的患者可能容易出现严重病程。专家小组建议在 COVID-19 大流行期间推迟使用细胞消耗型多发性硬化症疗法进行治疗。方法：我们报告了一例复发缓解型多发性硬化症患者，在克拉屈滨治疗第一周后 2 周出现了 COVID-19 肺炎。结果：尽管存在严重的淋巴细胞减少症（淋巴细胞绝对计数 240/μL），但患者的 COVID-19 病程为中度。结论：除了最大程度的支持治疗外，这可能是由于克拉屈滨减少了炎症反应，这可能在很大程度上导致了 COVID-19 肺炎的严重病程。
Background: Most cases of COVID-19 are considered mild, but patients with immunosuppressant treatment might be prone to severe courses of disease. Expert panels advise to delay treatment with cell-depleting MS therapies during the COVID-19 pandemic. Methods: We report a case of a patient with relapsing-remitting multiple sclerosis who developed COVID-19 pneumonia 2 weeks after the first week of cladribine therapy. Results: Despite a severe lymphopenia (absolute lymphocyte count 240/mu L), the patient had a moderate course of COVID-19. Conclusion: Apart from maximal supportive treatment, this could be due to cladribine reducing inflammatory response, which probably contributes considerably to severe courses of COVID-19 pneumonia.